Immune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown. We evaluated ipilimumab and nivolumab in patients with metastatic RCC after prior treatment with anti-PD-1 pathway-targeted therapy.
Patients with metastatic RCC who received prior anti-PD-1 pathway-targeted therapy and subsequently received ipilimumab and nivolumab were reviewed. Objective response rate and progression-free survival per investigator assessment were recorded. Toxicity of ipilimumab and nivolumab was also assessed.
Forty-five patients with metastatic RCC were included. All patients (100%) received prior ICIs targeting the PD-1 pathway. The median age was 62 years (range, 21-82 years). At a median follow-up of 12 months, the objective response rate to ipilimumab and nivolumab was 20%. The median progression-free survival while on ipilimumab and nivolumab was 4 months (range, 0.8-19 months). Immune-related adverse events (irAEs) of any grade with ipilimumab and nivolumab were recorded in 29 (64%) of the 45 patients; grade 3 irAEs were recorded in 6 (13%) of the 45 patients.
Ipilimumab and nivolumab demonstrated antitumor activity with acceptable toxicity in patients with metastatic RCC who had prior treatment with checkpoint inhibition.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jun 03 [Epub ahead of print]
Anita Gul, Tyler F Stewart, Charlene M Mantia, Neil J Shah, Emily Stern Gatof, Ying Long, Kimberly D Allman, Moshe C Ornstein, Hans J Hammers, David F McDermott, Michael B Atkins, Michael Hurwitz, Brian I Rini
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH., Yale Cancer Center, New Haven, CT., Beth Israel Deaconess Medical Center, Boston, MA., Georgetown Lombardi Comprehensive Cancer Center, Washington, DC., The University of Texas Southwestern Medical Center, Dallas, TX.